Assessing prostate cancer growth with mRNA of spermine metabolic enzymes

Cancer Biology and Therapy

Volumn 9, Issue 9, 2010, Pages 736-742

  Kaul, David ^a,b   Wu, Chin Lee ^a   Adkins, Christen B ^a   Jordan, Kate W ^a   Defeo, Elita M ^a   Habbel, Piet ^b   Peterson, Randall T ^a   McDougal, W Scott ^a   Pohl, Ute ^a   Cheng, Leo L ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Laser capture microdissection; Ornithine decarboxylase; Prostate cancer; PSA velocity; Real time quantitative PCR; Spermine

Indexed keywords

ACYLTRANSFERASE; ADENOSYLMETHIONINE DECARBOXYLASE; ANTIZYME; MESSENGER RNA; ORNITHINE DECARBOXYLASE; PROSTATE SPECIFIC ANTIGEN; SPERMIDINE/SPERMINE N1 ACETYLTRANSFERASE; SPERMINE; UNCLASSIFIED DRUG; DIAMINE ACETYLTRANSFERASE; DIAMINE N-ACETYLTRANSFERASE; MYC PROTEIN; MYC PROTEIN, HUMAN; PROTEIN; SPERMINE N1 ACETYLTRANSFERASE;

ARTICLE; CANCER GROWTH; CARCINOGENESIS; CLINICAL ARTICLE; GROWTH RATE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LASER CAPTURE MICRODISSECTION; LASER MICRODISSECTION; MAGNETIC SECTOR MASS SPECTROMETRY; MALE; METABOLISM; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; ONCOGENE C MYC; PROSTATE CANCER; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SCREENING TEST; SIGNAL TRANSDUCTION; ADULT; AGED; CELL PROLIFERATION; ENZYMOLOGY; GENETICS; LASER; MIDDLE AGED; PATHOLOGY; PROSTATE TUMOR; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; CANCER CELL; DISEASE ASSOCIATION; PROTEIN DEGRADATION;

ACETYLTRANSFERASES; ADULT; AGED; CELL PROLIFERATION; HUMANS; LASERS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; ORNITHINE DECARBOXYLASE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PROTEINS; PROTO-ONCOGENE PROTEINS C-MYC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SPERMINE;

EID: 79952019903     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.9.9.11549     Document Type: Article

References (28)

1. Chodak GW, Thisted RA, Gerber GS, Johansson JE, Adolfsson J, Jones GW, et al. Results of conservative management of clinically localized prostate cancer. N Engl J Med 1994; 330:242-8. (Pubitemid 24034136)
2. Johansson JE, Holmberg L, Johansson S, Bergstrom R, Adami HO. Fifteen-year survival in prostate cancer. A prospective, population-based study in Sweden. Jama 1997; 277:467-71.
3. Johansson JE, Adami HO, Andersson SO, Bergstrom R, Holmberg L, Krusemo UB. High 10-year survival rate in patients with early, untreated prostatic cancer. Jama 1992; 267:2191-6.
4. Andriole GL, Crawford ED, Grubb RL, 3rd, Buys SS, Chia D, Church TR, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009; 360:1310-9.
5. Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009; 360:1320-8.
6. Smith R, Litwin M, Lu Y, Zetter B. Identification of an endogenous inhibitor of prostate carcinoma cell growth. Nature Med 1995; 1:1040-5.
7. Gerner EW, Meyskens FL Jr. Polyamines and cancer: old molecules, new understanding. Nat Rev Cancer 2004; 4:781-92.
8. Cheng LL, Wu C, Smith MR, Gonzalez RG. Non-destructive quantitation of spermine in human prostate tissue samples using HRMAS 1H NMR spectroscopy at 9.4 T. FEBS Lett 2001; 494:112-6. (Pubitemid 32289382)
9. van der Graaf M, Schipper RG, Oosterhof GO, Schalken JA, Verhofstad AA, Heerschap A. Proton MR spectroscopy of prostatic tissue focused on the detection of spermine, a possible biomarker of malignant behavior in prostate cancer. Magma 2000; 10:153-9.
10. Simoneau AR, Gerner EW, Phung M, McLaren CE, Meyskens FL Jr. Alpha-difluoromethylornithine and polyamine levels in the human prostate: results of a phase IIa trial. J Natl Cancer Inst 2001; 93:57-9. (Pubitemid 32060891)
11. Simoneau AR, Gerner EW, Nagle R, Ziogas A, Fujikawa-Brooks S, Yerushalmi H, et al. The effect of difluoromethylornithine on decreasing prostate size and polyamines in men: results of a year-long phase IIb randomized placebo-controlled chemoprevention trial. Cancer Epidemiol Biomarkers Prev 2008; 17:292-9.
12. Gerner EW, Ignatenko NA, Lance P, Hurley LH. A comprehensive strategy to combat colon cancer targeting the adenomatous polyposis coli tumor suppressor gene. Ann N Y Acad Sci 2005; 1059:97-105. (Pubitemid 43211615)
13. Cheng LL, Ma MJ, Becerra L, Ptak T, Tracey I, Lackner A, et al. Quantitative neuropathology by high resolution magic angle spinning proton magnetic resonance spectroscopy. Proc Natl Acad Sci USA 1997; 94:6408-13.
14. Cheng LL, Lean CL, Bogdanova A, Wright SC Jr, Ackerman JL, Brady TJ, et al. Enhanced resolution of proton NMR spectra of malignant lymph nodes using magic-angle spinning. Magn Reson Med 1996; 36:653-8. (Pubitemid 26376702)
15. Cheng LL, Burns MA, Taylor JL, He W, Halpern EF, McDougal WS, et al. Metabolic characterization of human prostate cancer with tissue magnetic resonance spectroscopy. Cancer Res 2005; 65:3030-4. (Pubitemid 40524579)
16. Cheng LL, Wu C, Smith MR, Gonzalez RG. Non-destructive quantitation of spermine in human prostate tissue samples using HRMAS 1H NMR spectroscopy at 9.4 T. FEBS Lett 2001; 494:112-6. (Pubitemid 32289382)
17. Hansel DE, Demarzo AM, Platz EA, Jadallah S, Hicks J, Epstein JI, et al. Early prostate cancer antigen expression in predicting presence of prostate cancer in men with histologically negative biopsies. J Urol 2007; 177:1736-40. (Pubitemid 46560651)
18. Kee K, Foster BA, Merali S, Kramer DL, Hensen ML, Diegelman P, et al. Activated polyamine catabolism depletes acetyl-CoA pools and suppresses prostate tumor growth in TRAMP mice. J Biol Chem 2004; 279:40076-83. (Pubitemid 39258282)
19. Kameji T, Pegg AE. Inhibition of translation of mRNAs for ornithine decarboxylase and S-adenosylmethionine decarboxylase by polyamines. J Biol Chem 1987; 262:2427-30.
20. Auvinen M, Jarvinen K, Hotti A, Okkeri J, Laitinen J, Janne OA, et al. Transcriptional regulation of the ornithine decarboxylase gene by c-Myc/Max/Mad network and retinoblastoma protein interacting with c-Myc. Int J Biochem Cell Biol 2003; 35:496-521. (Pubitemid 36140071)
21. Shantz LM, Levin VA. Regulation of ornithine decarboxylase during oncogenic transformation: mechanisms and therapeutic potential. Amino Acids 2007; 33:213-23.
22. Chien J, Narita K, Rattan R, Giri S, Shridhar R, Staub J, et al. A role for candidate tumor-suppressor gene TCEAL7 in the regulation of c-Myc activity, cyclin D1 levels and cellular transformation. Oncogene 2008; 27:7223-34.
23. Chattopadhyay MK, Park MH, Tabor H. Hypusine modification for growth is the major function of spermidine in Saccharomyces cerevisiae polyamine auxotrophs grown in limiting spermidine. Proc Natl Acad Sci USA 2008; 105:6554-9.
24. Lee SB, Park JH, Kaevel J, Sramkova M, Weigert R, Park MH. The effect of hypusine modification on the intracellular localization of eIF5A. Biochem Biophys Res Commun 2009; 383:497-502.
25. D'Amico AV, Renshaw AA, Sussman B, Chen MH. Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy. Jama 2005; 294:440-7. (Pubitemid 41124176)
26. D'Amico AV, Chen MH, Roehl KA, Catalona WJ. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 2004; 351:125-35.
27. Patel DA, Presti JC Jr, McNeal JE, Gill H, Brooks JD, King CR. Preoperative PSA velocity is an independent prognostic factor for relapse after radical prostatectomy. J Clin Oncol 2005; 23:6157-62. (Pubitemid 46300234)
28. Burns MA, Taylor JL, Wu CL, Zepeda AG, Bielecki A, Cory D, et al. Reduction of spinning sidebands in proton NMR of human prostate tissue with slow high-resolution magic angle spinning. Magn Reson Med 2005; 54:34-42. (Pubitemid 40898394)